u/gallbladder_gary

API transparency is the question that separates good compounders from sketchy ones

You have restated the marketing copy. What is the actual substance here.

This is correct. The shortage list does expire and the rules change.

Not to be pedantic but 503A and state board are being used interchangeably and they are not interchangeable in real life.

API transparency is the question that separates good compounders from sketchy ones

Disagree. What you are describing is consistent with purity, not with what you concluded.

the related substances line is where the story is

Small correction: the trial was 16 weeks, not 26. Does not change your point but people will quote it.

Strongly agree. Mass% and area% are answering different questions on the same document.

Batch number and date of analysis? Both are load-bearing.

pricing posts need date and currency

regulatory claims need a citation to the actual rule, not interpretation

Yes, exactly this, and it is the bit that took me 66 weeks to accept.

Water content matters more than people think. If a vial is carrying residual moisture, your "10mg" is not 10mg of peptide.

the 503A/503B distinction is load-bearing, do not blur it

Asked 7 compounders about API source. One told me, one dodged, one said they cannot say. The answer is the signal.

EMA and national agency claims need citation

Yes, exactly this, and it is the bit that took me 3 weeks to accept.

What is the actual shortage list status right now?

private and public prescription routes differ

API transparency is the question that separates good compounders from sketchy ones

Did they tell you their API source or dodge the question?